THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B : A CASE REPORT

Authors

  • Oktavia Setyaningrum Faculty of Medicine, Tarumanagara University, Jakarta
  • Albert Tri Rustamadji Department of Internal Medicine, Soewondo Pati Regional Hospital, Central Java

DOI:

https://doi.org/10.31004/prepotif.v8i3.34926

Keywords:

hepatitis B kronis, kekambuhan klinis, kekambuhan virologis, pemantauan pasien, terapi antivirus

Abstract

Infeksi virus hepatitis B (HBV) kronis menimbulkan tantangan kesehatan masyarakat yang besar, yang berpotensi menyebabkan sirosis dan karsinoma hepatoseluler (HCC). Terapi antivirus yang efektif telah meningkatkan prognosis pasien, tetapi menghentikan pengobatan dapat mengakibatkan hasil yang merugikan. Seorang pria berusia 61 tahun dengan riwayat hepatitis B menghentikan terapi antivirus, yang menyebabkan penyakit kuning yang memburuk, nyeri perut, dan gejala lainnya. Pemeriksaan mengungkapkan disfungsi hati yang signifikan. Hepatitis B merupakan masalah kesehatan global. Analog nukleosida (NA) jangka panjang sangat penting untuk mengelola HBV. Penghentian NA sebelum waktunya dapat menyebabkan kekambuhan virologis dan klinis, yang memerlukan kepatuhan ketat terhadap pengobatan dan pemantauan berkelanjutan. Kasus ini menggarisbawahi pentingnya mematuhi terapi antivirus dan menyoroti perlunya pemantauan pasien yang waspada untuk mencegah penurunan kesehatan yang parah.

References

Agarwal, J. (2022). Recurrent Jaundice in a Child: Case based Reviews.

Akbar, S. M. F., Yoshida, O., & Hiasa, Y. (2022). Immune therapies against chronic hepatitis B. Journal of Gastroenterology, 57(8), 517-528.

Dimond, B. (2008). The mental capacity act 2005 and decision-making: code of practice. British Journal of Nursing, 7(2), 110-112

Hall, S. A. L., Vogrin, S., Wawryk, O., Burns, G. S., Visvanathan, K., Sundararajan, V., & Thompson, A. (2022). Discontinuation of nucleot (s) ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut, 71(8), 1629-1641.

Inoue, T., Matsui, T., & Tanaka, Y. (2021). Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatology Research, 51(10), 1033-1043.

Kaewdech, A., & Sripongpun, P. (2021). Challenges in the discontinuation of chronic hepatitis B antiviral agents. World Journal of Hepatology, 13(9), 1042.

Yousef, A. S., Said, M. T., Mohammed, A. E., & Zaki, M. A. (2021). Outcome of screening of patients with hepatitis B virus infection. SVU-International Journal of Medical Sciences, 4(1), 80-87.

Zhao, R. H., Shi, Y., Zhao, H., Wu, W., & Sheng, J. F. (2018). Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert review of gastroenterology & hepatology, 12(4), 341-350

Tan, L., Xu, S. L., Mo, Z. S., Liu, J. R., Gan, W. Q., Chen, J. H., ... & Wu, Z. Q. (2021). The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen-positive and-negative chronic hepatitis B patients. Annals of Translational Medicine, 9(18).

Thomas, D. L., Kiser, J. J., & Baum, M. M. (2022). Long-acting treatments for hepatitis B. Clinical Infectious Diseases, 75(Supplement_4), S517-S524.

Upadhyay, P., Lal, B. B., Sood, V., Khanna, R., Gupta, E., Rastogi, A., & Alam, S. (2022). Incidence and Predictors of Relapse After Stopping Antiviral Therapy in Pediatric Chronic Hepatitis B. The Pediatric Infectious Disease Journal, 41(9), 714-719

Downloads

Published

2024-10-18

How to Cite

Setyaningrum, O., & Tri Rustamadji, A. (2024). THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B : A CASE REPORT. PREPOTIF : JURNAL KESEHATAN MASYARAKAT, 8(3), 5155–5160. https://doi.org/10.31004/prepotif.v8i3.34926

Issue

Vol. 8 No. 3 (2024): DESEMBER 2024

Section

Articles

License

Copyright (c) 2024 Oktavia Setyaningrum, Albert Tri Rustamadji

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).